A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-10

Study Completion Date

2025-08-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of the study is to learn what happens to levels of MK-7602 in a healthy person's body over time. Researchers will compare what happens to MK-7602 in the body when it is given with or without another medicine called efavirenz, and when it is given with or without a meal.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efavirenz Comparative Bioavailability

NCT01704898

Healthy

COMPLETED PHASE4

Pharmacokinetic Interaction Study of Efavirenz and American Ginseng in Healthy Volunteers

NCT01136928

Healthy Volunteers

COMPLETED PHASE1

A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function

NCT06734208

Hepatic Impairment

COMPLETED PHASE1

A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults

NCT06347861

Healthy

COMPLETED PHASE1

A Study to Evaluate the Effect of Formulation and Food on MK-1084 in Healthy Adult Participants (MK-1084-011)

NCT06942741

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Part 1 has a single arm. Part 2 will enroll participants in a crossover design, randomized between 6 different treatment sequences.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part 2, Sequence 3: Moderate-Fat Meal→Low-Fat Meal→Fasted

Participants will be administered MK-7602 with a moderate-fat meal, then with a low-fat meal, then in the fasted state.

Group Type EXPERIMENTAL

MK-7602

Intervention Type DRUG

Capsule

Part 2, Sequence 4: Moderate-Fat Meal→Fasted→Low-Fat Meal

Participants will be administered MK-7602 with a moderate-fat meal, then in the fasted state, then with a low-fat meal.

Group Type EXPERIMENTAL

MK-7602

Intervention Type DRUG

Capsule

Part 2, Sequence 5: Low-Fat Meal→Fasted→Moderate-Fat Meal

Participants will be administered MK-7602 with a low-fat meal, then in the fasted state, then with a moderate-fat meal.

Group Type EXPERIMENTAL

MK-7602

Intervention Type DRUG

Capsule

Part 2, Sequence 6: Low-Fat Meal→Moderate-Fat Meal→Fasted

Participants will be administered MK-7602 with a low-fat meal, then with a moderate-fat meal, then in the fasted state.

Group Type EXPERIMENTAL

MK-7602

Intervention Type DRUG

Capsule

Part 1: MK-7602 + Efavirenz

Participants will be administered MK-7602 and efavirenz.

Group Type EXPERIMENTAL

MK-7602

Intervention Type DRUG

Capsule

Efavirenz

Intervention Type DRUG

Tablet

Part 2, Sequence 1: Fasted→Moderate-Fat Meal→Low-Fat Meal

Participants will be administered MK-7602 in the fasted state, then with a moderate-fat meal, then with a low-fat meal.

Group Type EXPERIMENTAL

MK-7602

Intervention Type DRUG

Capsule

Part 2, Sequence 2: Fasted→Low-Fat Meal→Moderate-Fat Meal

Participants will be administered MK-7602 in the fasted state, then with a low-fat meal, then with a moderate-fat meal.

Group Type EXPERIMENTAL

MK-7602

Intervention Type DRUG

Capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK-7602

Capsule

Intervention Type DRUG

Efavirenz

Tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MK-0831

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Has a body-mass index (BMI) of 18 to 32 kg/m\^2.

Exclusion Criteria

* Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and seizures) abnormalities or diseases.
* Has a history of cancer (malignancy)
* Has positive test(s) for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus (HIV)

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes